KalVista Pharmaceuticals (KALV) Receivables Refunds (2017 - 2025)
KalVista Pharmaceuticals recorded quarterly Receivables Refunds of $561000.0 in Q3 2025, down 59.44% quarter-over-quarter from $1.4 million in Q2 2025, and down 41.5% year-over-year from $959000.0 in Q3 2024.
KalVista Pharmaceuticals' Receivables Refunds history runs 9 years deep, the most recent figure standing at $561000.0 for Q3 2025.
- In Q3 2025, Receivables Refunds fell 41.5% year-over-year to $561000.0; the TTM figure through Jul 2025 stood at $561000.0 (down 41.5% YoY), while the FY2025 annual figure was $1.4 million, down 83.54% from the prior year.
- Receivables Refunds came in at $561000.0 for Q3 2025 at KalVista Pharmaceuticals, down from $1.4 million in the prior quarter.
- In the past five years, Receivables Refunds ranged from a high of $20.0 million in Q4 2022 to a low of $263000.0 in Q1 2024.
- A 5-year average of $10.7 million and a median of $11.4 million in 2024 frame the typical range for Receivables Refunds.
- Across the five-year window, Receivables Refunds jumped 48.73% in 2022 and slumped 97.79% in 2024, its largest moves.
- KalVista Pharmaceuticals' Receivables Refunds stood at $17.4 million in 2021, then climbed by 15.12% to $20.0 million in 2022, then retreated by 0.26% to $20.0 million in 2023, then sank by 42.85% to $11.4 million in 2024, then slumped by 95.09% to $561000.0 in 2025.
- According to Business Quant data, Receivables Refunds over the past three periods registered $561000.0, $1.4 million, and $11.4 million for Q3 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Refund Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn | 561,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | 561,000.00 |
| Apr 30, 2025 | 1.38 Mn |
| Dec 31, 2024 | 11.42 Mn |
| Oct 31, 2024 | 965,000.00 |
| Jul 31, 2024 | 959,000.00 |
| Apr 30, 2024 | 8.40 Mn |
| Jan 31, 2024 | 263,000.00 |
| Oct 31, 2023 | 19.98 Mn |
| Jul 31, 2023 | 19.06 Mn |
| Apr 30, 2023 | 16.60 Mn |
| Jan 31, 2023 | 11.89 Mn |
| Oct 31, 2022 | 20.03 Mn |
| Jul 31, 2022 | 17.25 Mn |
| Apr 30, 2022 | 14.10 Mn |
| Jan 31, 2022 | 11.29 Mn |
| Oct 31, 2021 | 17.40 Mn |
| Jul 31, 2021 | 13.61 Mn |
| Apr 30, 2021 | 10.40 Mn |
| Jan 31, 2021 | 7.59 Mn |
| Oct 31, 2020 | 14.69 Mn |
| Jul 31, 2020 | 12.64 Mn |
| Apr 30, 2020 | 16.53 Mn |
| Jan 31, 2020 | 14.80 Mn |
| Oct 31, 2019 | 11.81 Mn |
| Jul 31, 2019 | 12.63 Mn |
| Apr 30, 2019 | 11.32 Mn |
| Jan 31, 2019 | 8.97 Mn |
| Oct 31, 2018 | 7.03 Mn |
| Jul 31, 2018 | 5.60 Mn |
| Apr 30, 2018 | 6.83 Mn |
| Jan 31, 2018 | 4.99 Mn |
| Oct 31, 2017 | 3.72 Mn |
| Jul 31, 2017 | 2.82 Mn |
| Apr 30, 2017 | 2.25 Mn |
| Jan 31, 2017 | 2.84 Mn |